Clinical Trial Update: Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 clinical trial is evaluating adaptive BRAF-MEK inhibitor therapy for advanced BRAF-mutant melanoma. The study is currently active but not recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Melanoma (Skin), Skin Cancer | EARLY_Phase 1 | Status: ACTIVE_NOT_RECRUITING